1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]-

Request For Quotation
1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]- Suppliers list
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]- Basic information
Product Name:1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]-
Synonyms:1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]-;DDO-2093
CAS:2250024-74-7
MF:C29H37ClFN9O3
MW:614.11
EINECS:
Product Categories:
Mol File:2250024-74-7.mol
1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]- Structure
1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]- Chemical Properties
density 1.44±0.1 g/cm3(Predicted)
pka11.08±0.70(Predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]- Usage And Synthesis
UsesDDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex[1].
in vivo

DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner[1].

Animal Model:Female nude mice (MV4-11 human leukemia cancer xenografts)[1]
Dosage:20 mg/kg, 40 mg/kg and 80 mg/kg
Administration:Intraperitoneal injection; every other day for 21 days
Result:Had the tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.
References[1] Chen W, et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity [published online ahead of print, 2021 Jun 28]. Eur J Med Chem. 2021;223:113677. DOI:10.1016/j.ejmech.2021.113677
1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]- Preparation Products And Raw materials
Tag:1H-1,2,3-Triazole-4-carboxamide, 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methyl-1-piperazinyl)phenyl]-N-[3-(4-morpholinyl)propyl]-(2250024-74-7) Related Product Information
EPZ015666 GSK-3326595 UNC-0642 UNC0638 SGC0946 GSK591